Efficacy and tolerability of three topical acne treatments by body mass index: post hoc analysis including overweight and obese patients
Background Acne prevalence may be higher in overweight/obese individuals, potentially due to hormonal, inflammatory, and/or dietary factors. However, the effects of body mass index (BMI) on topical acne treatments are largely unknown. Methods Post hoc analyses of changes in inflammatory/noninflammat...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-08-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09546634.2022.2071823 |
| _version_ | 1797683465100984320 |
|---|---|
| author | Jonette Keri Fran E. Cook-Bolden Lawrence Green Leon H. Kircik Hilary Baldwin William Philip Werschler Eric Guenin Radhakrishnan Pillai Varsha Bhatt |
| author_facet | Jonette Keri Fran E. Cook-Bolden Lawrence Green Leon H. Kircik Hilary Baldwin William Philip Werschler Eric Guenin Radhakrishnan Pillai Varsha Bhatt |
| author_sort | Jonette Keri |
| collection | DOAJ |
| description | Background Acne prevalence may be higher in overweight/obese individuals, potentially due to hormonal, inflammatory, and/or dietary factors. However, the effects of body mass index (BMI) on topical acne treatments are largely unknown. Methods Post hoc analyses of changes in inflammatory/noninflammatory lesions and treatment success were conducted using phase 3 data: clindamycin phosphate/benzoyl peroxide (CP/BPO) 1.2%/3.75% gel (NCT01701024); tretinoin 0.05% lotion (NCT02965456 and NCT02932306; pooled); and tazarotene 0.045% lotion (NCT03168321 and NCT03168334; pooled). Data were analyzed by BMI subgroups: <25kg/m2 (underweight-to-normal), 25-<30kg/m2 (overweight), and ≥30kg/m2 (obese). Results Among participants analyzed (CP/BPO = 495; tretinoin = 1,636; tazarotene = 1,612), ∼20–25% were overweight and 15–20% were obese. At week 12, mean percent changes from baseline in inflammatory lesions were: CP/BPO (overweight: −63.2%, obese: −56.0%); tretinoin (−57.6%, −53.1%); tazarotene (−59.9%, −56.8%). Mean changes in noninflammatory lesions were: CP/BPO (−54.2%, −50.8%); tretinoin (−51.6%, −44.9%); tazarotene (−56.7%, −54.6%). Treatment success rates with active treatment ranged from 16.2% to 33.5% across BMI groups. Conclusions CP/BPO 1.2%/3.75% gel, tretinoin 0.05% lotion, and tazarotene 0.045% lotion were all effective in reducing acne lesions by ≥45% in overweight/obese patients with moderate-to-severe acne, comparable to the underweight-to-normal group. Efficacy of these topical acne treatments is not greatly impacted by BMI and may be affected more by the formulation. |
| first_indexed | 2024-03-12T00:15:53Z |
| format | Article |
| id | doaj.art-49a097b9d91d404c905d13a0b7b4535b |
| institution | Directory Open Access Journal |
| issn | 0954-6634 1471-1753 |
| language | English |
| last_indexed | 2024-03-12T00:15:53Z |
| publishDate | 2022-08-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj.art-49a097b9d91d404c905d13a0b7b4535b2023-09-15T14:28:52ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532022-08-013362790279910.1080/09546634.2022.20718232071823Efficacy and tolerability of three topical acne treatments by body mass index: post hoc analysis including overweight and obese patientsJonette Keri0Fran E. Cook-Bolden1Lawrence Green2Leon H. Kircik3Hilary Baldwin4William Philip Werschler5Eric Guenin6Radhakrishnan Pillai7Varsha Bhatt8University of MiamiWeill Cornell Medical CollegeDepartment of Dermatology, George Washington University School of MedicineIcahn School of Medicine at Mount SinaiThe Acne Treatment and Research CenterESFCOM Washington State UniversityOrtho DermatologicsBausch Health US, LLCBausch Health US, LLCBackground Acne prevalence may be higher in overweight/obese individuals, potentially due to hormonal, inflammatory, and/or dietary factors. However, the effects of body mass index (BMI) on topical acne treatments are largely unknown. Methods Post hoc analyses of changes in inflammatory/noninflammatory lesions and treatment success were conducted using phase 3 data: clindamycin phosphate/benzoyl peroxide (CP/BPO) 1.2%/3.75% gel (NCT01701024); tretinoin 0.05% lotion (NCT02965456 and NCT02932306; pooled); and tazarotene 0.045% lotion (NCT03168321 and NCT03168334; pooled). Data were analyzed by BMI subgroups: <25kg/m2 (underweight-to-normal), 25-<30kg/m2 (overweight), and ≥30kg/m2 (obese). Results Among participants analyzed (CP/BPO = 495; tretinoin = 1,636; tazarotene = 1,612), ∼20–25% were overweight and 15–20% were obese. At week 12, mean percent changes from baseline in inflammatory lesions were: CP/BPO (overweight: −63.2%, obese: −56.0%); tretinoin (−57.6%, −53.1%); tazarotene (−59.9%, −56.8%). Mean changes in noninflammatory lesions were: CP/BPO (−54.2%, −50.8%); tretinoin (−51.6%, −44.9%); tazarotene (−56.7%, −54.6%). Treatment success rates with active treatment ranged from 16.2% to 33.5% across BMI groups. Conclusions CP/BPO 1.2%/3.75% gel, tretinoin 0.05% lotion, and tazarotene 0.045% lotion were all effective in reducing acne lesions by ≥45% in overweight/obese patients with moderate-to-severe acne, comparable to the underweight-to-normal group. Efficacy of these topical acne treatments is not greatly impacted by BMI and may be affected more by the formulation.http://dx.doi.org/10.1080/09546634.2022.2071823topicalacnebmiretinoidantibioticphase 3tazarotenetretinoinclindamycin phosphatebenzoyl peroxide |
| spellingShingle | Jonette Keri Fran E. Cook-Bolden Lawrence Green Leon H. Kircik Hilary Baldwin William Philip Werschler Eric Guenin Radhakrishnan Pillai Varsha Bhatt Efficacy and tolerability of three topical acne treatments by body mass index: post hoc analysis including overweight and obese patients Journal of Dermatological Treatment topical acne bmi retinoid antibiotic phase 3 tazarotene tretinoin clindamycin phosphate benzoyl peroxide |
| title | Efficacy and tolerability of three topical acne treatments by body mass index: post hoc analysis including overweight and obese patients |
| title_full | Efficacy and tolerability of three topical acne treatments by body mass index: post hoc analysis including overweight and obese patients |
| title_fullStr | Efficacy and tolerability of three topical acne treatments by body mass index: post hoc analysis including overweight and obese patients |
| title_full_unstemmed | Efficacy and tolerability of three topical acne treatments by body mass index: post hoc analysis including overweight and obese patients |
| title_short | Efficacy and tolerability of three topical acne treatments by body mass index: post hoc analysis including overweight and obese patients |
| title_sort | efficacy and tolerability of three topical acne treatments by body mass index post hoc analysis including overweight and obese patients |
| topic | topical acne bmi retinoid antibiotic phase 3 tazarotene tretinoin clindamycin phosphate benzoyl peroxide |
| url | http://dx.doi.org/10.1080/09546634.2022.2071823 |
| work_keys_str_mv | AT jonettekeri efficacyandtolerabilityofthreetopicalacnetreatmentsbybodymassindexposthocanalysisincludingoverweightandobesepatients AT franecookbolden efficacyandtolerabilityofthreetopicalacnetreatmentsbybodymassindexposthocanalysisincludingoverweightandobesepatients AT lawrencegreen efficacyandtolerabilityofthreetopicalacnetreatmentsbybodymassindexposthocanalysisincludingoverweightandobesepatients AT leonhkircik efficacyandtolerabilityofthreetopicalacnetreatmentsbybodymassindexposthocanalysisincludingoverweightandobesepatients AT hilarybaldwin efficacyandtolerabilityofthreetopicalacnetreatmentsbybodymassindexposthocanalysisincludingoverweightandobesepatients AT williamphilipwerschler efficacyandtolerabilityofthreetopicalacnetreatmentsbybodymassindexposthocanalysisincludingoverweightandobesepatients AT ericguenin efficacyandtolerabilityofthreetopicalacnetreatmentsbybodymassindexposthocanalysisincludingoverweightandobesepatients AT radhakrishnanpillai efficacyandtolerabilityofthreetopicalacnetreatmentsbybodymassindexposthocanalysisincludingoverweightandobesepatients AT varshabhatt efficacyandtolerabilityofthreetopicalacnetreatmentsbybodymassindexposthocanalysisincludingoverweightandobesepatients |